What is Swoop?
Swoop operates at the intersection of artificial intelligence, machine learning, and real-world evidence to transform how pharmaceutical brands interact with patient populations. The company provides a HIPAA-certified and NAI-accredited system of engagement that utilizes a vast data universe of over 300 million de-identified patients and 65 billion anonymous consumer interactions. By identifying unique target audiences and facilitating cross-channel marketing strategies, Swoop empowers patients to become active participants in their treatment journeys while driving measurable Rx lift for its enterprise clients. This data-driven approach ensures that pharmaceutical companies can deliver precise, actionable education regarding disease states and therapeutic options, effectively optimizing the patient-provider ecosystem.
How much funding has Swoop raised?
Swoop has raised a total of $13.4M across 4 funding rounds:
Series A
$4.8M
Other Financing Round
$3M
Series B
$3.5M
Debt
$2.1M
Series A (2011): $4.8M with participation from General Catalyst Partners, Valhalla Partners, and U.S. Venture Partners
Other Financing Round (2012): $3M led by U.S. Venture Partners and Valhalla Partners
Series B (2013): $3.5M supported by U.S. Venture Partners
Debt (2014): $2.1M featuring U.S. Venture Partners
Key Investors in Swoop
General Catalyst Partners
A venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors, providing strategic capital to build enduring enterprises.
Valhalla Partners
A leading venture capital firm that assists entrepreneurs by offering seasoned advice and best practices developed through decades of investment experience.
U.S. Venture Partners
A prominent Silicon Valley venture capital firm dedicated to collaborating with entrepreneurs to develop transformative companies across healthcare and enterprise software sectors.
What's next for Swoop?
With a robust foundation established through successive funding rounds, Swoop is well-positioned to scale its proprietary AI-driven engagement platform. The company's strategic roadmap likely involves expanding its data universe and deepening its integration within the healthcare marketing landscape. As the demand for personalized patient engagement grows, Swoop's ability to leverage social determinants of health and outcomes research will be critical in maintaining its competitive advantage. Future growth will likely focus on enhancing audience quality and conversion metrics, further cementing its status as an essential partner for global pharmaceutical brands seeking to navigate the complexities of modern patient education and therapy adherence.
See full Swoop company page
